- Conditions
- Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)
- Interventions
- Ipilimumab, Osimertinib
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 50,434
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer
- Interventions
- margetuximab, Retifanlimab, Tebotelimab, Trastuzumab, Chemotherapy
- Biological · Other
- Lead sponsor
- MacroGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 28
- States / cities
- Scottsdale, Arizona • Duarte, California • Los Angeles, California + 25 more
- Conditions
- Cancer, Breast, Cancer, Colorectal, Cancer, Prostate
- Interventions
- Not listed
- Lead sponsor
- Loma Linda University
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 96,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2028
- U.S. locations
- 1
- States / cities
- Loma Linda, California
- Conditions
- Estrogen Receptor Positive Breast Cancer
- Interventions
- [18F]Fluoroestradiol (FES) PET/CT
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Ovarian Cancer
- Interventions
- Glufosfamide
- Drug
- Lead sponsor
- Eleison Pharmaceuticals LLC.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Greenbrae, California + 7 more
- Conditions
- Survivorship, Cancer, Symptoms and Signs
- Interventions
- POSTHOC app
- Behavioral
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Breast Cancer
- Interventions
- Tucatinib in Combination with Palbociclib and Letrozole
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 6
- States / cities
- Tucson, Arizona • Aurora, Colorado • Chicago, Illinois + 3 more
- Conditions
- Renal Cancer, Tumor, Solid, Kidney Cancer, Tumor, Tumor, Benign
- Interventions
- HistoSonics Edison System
- Device
- Lead sponsor
- HistoSonics, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Mission Viejo, California • New Haven, Connecticut + 10 more
- Conditions
- Gastrointestinal Cancer
- Interventions
- My Sleep Our Sleep (MSOS) Program, Brief Behavioral Treatment for Insomnia (BBTI)
- Behavioral
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Coral Gables, Florida • Pittsburgh, Pennsylvania
- Conditions
- Breast Cancer
- Interventions
- perillyl alcohol
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Carcinoma, Non Small Cell Lung
- Interventions
- gemcitabine, carboplatin, cisplatin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Neoplasms, Neoplasm Metastasis, Metastatic Gastrointestinal Carcinoid Tumor
- Interventions
- EMB-01
- Drug
- Lead sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Metastatic Cancer, Pancreatic Cancer
- Interventions
- fluorouracil, selective external radiation therapy, tomotherapy, yttrium Y 90 glass microspheres, yttrium Y 90 resin microspheres
- Drug · Radiation
- Lead sponsor
- Goshen Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Goshen, Indiana
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Tadalafil, Placebo
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 21 Years to 99 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Grade IV Glioma, Grade IV Astrocytoma, Glioblastoma Multiforme
- Interventions
- TVI-Brain-1
- Biological
- Lead sponsor
- TVAX Biomedical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 4
- States / cities
- Kansas City, Missouri • St Louis, Missouri • Dallas, Texas + 1 more
- Conditions
- Hodgkin's Lymphoma
- Interventions
- Obatoclax mesylate (GX15-070MS)
- Drug
- Lead sponsor
- Gemin X
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lung Cancer, Thoracic Cancer
- Interventions
- Not listed
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Breast Cancer
- Interventions
- therapeutic autologous dendritic cells, conventional surgery, neoadjuvant therapy
- Biological · Procedure
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Regorafenib (Stivarga, BAY73-4506), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 573 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 17
- States / cities
- Los Angeles, California • Orange, California • Aurora, Colorado + 13 more
- Conditions
- Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor, Metastatic Cancer, WNT Pathway, HCC, Desmoid, Microsatellite Stable Colorectal Cancer, Metastatic Castration-resistant Prostate Cancer, Familial Adenomatous Polyposis (FAP), Endometrial Carcinoma, Prostate Cancer, Microsatellite Instability-High Colorectal Cancer, Adamantinomatous Craniopharyngioma
- Interventions
- FOG-001, mFOLFOX-6, Nivolumab, Trifluridine/tipiracil, Bevacizumab
- Drug
- Lead sponsor
- Parabilis Medicines, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 619 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 25 more
- Conditions
- Breast Cancer, Solid Tumor, Adult
- Interventions
- APG-2575, Palbociclib
- Drug
- Lead sponsor
- Ascentage Pharma Group Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Austin, Texas • Houston, Texas + 1 more
- Conditions
- Osteomalacia
- Interventions
- 68Ga-DOTATATE PET/CT
- Combination Product
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Neuroendocrine Tumor, Islet Cell Tumor
- Interventions
- Sunitinib malate, Hepatic Artery Embolizations
- Drug · Procedure
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Lung Cancer Non Small Cell, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma Bladder
- Interventions
- IO102-IO103 in combination with pembrolizumab
- Drug
- Lead sponsor
- IO Biotech
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 9
- States / cities
- Duarte, California • Sacramento, California • San Diego, California + 6 more